Volition Appoints Dr. Ethel Rubin as an Independent Director

Core Points - VolitionRx Limited has appointed Dr. Ethel Rubin as an independent director effective September 30, 2024, and she will also serve on the Audit Committee and Compensation Committee [1][2][3] Company Overview - VolitionRx is a multi-national epigenetics company focused on advancing the science of epigenetics to improve outcomes for people and animals with life-altering diseases through earlier detection and monitoring [4][5] - The company is developing simple, cost-effective blood tests aimed at diagnosing and monitoring various diseases, including cancers and conditions associated with NETosis, such as sepsis [5][6] Leadership and Expertise - Dr. Ethel Rubin brings over 20 years of experience in the life sciences sector, having held leadership roles in organizations such as BioFortis, CSA Medical, and Medtronic, contributing to the launch of over 25 commercial products [2][3] - Guy Innes, Interim Chair of Volition, expressed confidence in Dr. Rubin's ability to support the company's commercialization efforts for its epigenetic solutions [3] Technology and Market Potential - Volition's Nu.Q® technology, which is already generating revenue in the animal health sector, has potential applications in human health for early detection and monitoring of diseases like cancer and sepsis [3][5]